{"id":3708,"date":"2018-12-04T15:31:16","date_gmt":"2018-12-04T10:01:16","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=3708"},"modified":"2021-07-24T12:57:08","modified_gmt":"2021-07-24T07:27:08","slug":"notizia-82","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-82","title":{"rendered":"Notizia"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>If dementia genes are found, drug discovery can be accelerated in brain disorders<\/strong><\/p>\n<p style=\"text-align: justify;\">The overproduction of a protein called <strong>tau<\/strong> has been detected in the neuron degeneration that causes <strong>Alzheimer\u2019s<\/strong> and other forms of dementia. But the exact genetic process that causes tau is still a mystery. Scientists of the <strong>University of California, Los Angeles<\/strong>, are trying to comprehend the genes that are involved in the tau overproduction. They ruminate that their findings could improve efforts to develop treatments for <a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-epidemiology-forecast\">Alzheimer\u2019s<\/a>, early-onset <a href=\"https:\/\/www.delveinsight.com\/report-store\/dementia-associated-with-alzheimers-disease-pipeline-insight\">dementia<\/a> and other brain diseases. The team also detected two gene clusters beset by mutations that cause tau overproduction. They stated their&nbsp;findings&nbsp;in the journal <strong>Nature Medicine<\/strong>.<\/p>\n<p style=\"text-align: justify;\"><strong>The luspatercept of Celgene passes phase 3 beta thalassemia trial<\/strong><\/p>\n<p style=\"text-align: justify;\">A<strong> phase 3 trial<\/strong> of <strong>Celgene\u2019s<\/strong> <strong>luspatercept<\/strong> in adults with <strong>beta-thalassemia<\/strong> has been succeeded. The late-phase success of Celgene will soon file for approval of its Acceleron-partnered blockbuster prospect. The trial of Celgene&nbsp;evaluated&nbsp;the ability of erythroid maturation agent luspatercept to decrease the need for adults with anaemia related to beta thalassemia to undergo red blood cell transfusions. Luspatercept was done to drive enhanced outcomes by targeting <strong>TGF-beta proteins<\/strong> involved in the maturation of <strong>red blood cells<\/strong>. The phase 3 trial delivered further evidence to bolster the use of luspatercept. About one-fifth of participants, who received luspatercept every three weeks experienced a 33% reduction in transfusion burden during weeks 13 to 24 of the trial, compared to 5% of people on placebo.<\/p>\n<p style=\"text-align: justify;\"><strong>Regeneron lists 80% complete response rate in lymphoma trial<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Regeneron\u2019s<\/strong> <strong>CD20xCD3<\/strong> bispecific antibody has&nbsp;accomplished&nbsp;an 80% complete response rate in a trial of patients with relapsed or <strong>refractory follicular <a href=\"https:\/\/www.delveinsight.com\/report-store\/b-cell-lymphomas-market\">lymphoma<\/a><\/strong>. The strong early signs of efficacy led Regeneron to aim for a potentially registrational<strong> phase 2 study<\/strong>. <strong>REGN1979<\/strong> is designed to bind to <strong>T cell surface antigen <a href=\"https:\/\/www.delveinsight.com\/report-store\/anti-cd3-antibody-pipeline-insight\">CD3<\/a><\/strong> and tumour-associated antigen CD20. By linking the immune and cancer cells, Regeneron thinks REGN1979 may trigger specific, local T cell activation and thereby drive cytotoxic attacks against tumour B cells. <strong>Regeneron Pharmaceuticals Inc<\/strong>., a biotechnology company headquartered in Eastview, near Tarrytown, New York, had reported early signs of antitumor activity at a meeting of the American Society of Hematology.<\/p>\n<p style=\"text-align: justify;\"><strong>H.pylori antibiotic of RedHill flies through phase 3<\/strong><\/p>\n<p style=\"text-align: justify;\">The lead asset of <strong>RedHill Biopharma<\/strong>,&nbsp;antibiotic cocktail&nbsp;<strong>RHB-105<\/strong>, defeated an <strong>amoxicillin<\/strong> combination in patients with <strong>H. pylori infection<\/strong>, topline phase 3 data. The results got RedHill, a biopharmaceutical company, for an <strong>FDA<\/strong> filing. RHB-105 is a combination of the antibiotics <strong>rifabutin and amoxicillin<\/strong>, and&nbsp;omeprazole, a proton pump inhibitor&nbsp;used&nbsp;to treat acidity in the stomach. The ERADICATE Hp2 study is a two-arm, randomized, double-blind, active comparator-controlled, the study involved 455 patients with dyspepsia, who also had H. pylori infection. Patients were allowed to receive four capsules three times a day for 14 days of either RHB-105 or of the active comparator, a combination of amoxicillin and omeprazole.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>If dementia genes are found, drug discovery can be accelerated in brain disorders The overproduction of a protein called tau has been detected in the neuron degeneration that causes Alzheimer\u2019s and other forms of dementia. But the exact genetic process that causes tau is still a mystery. Scientists of the University of California, Los Angeles, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3711,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1856,2273,109,2265,155,704,2274,2260,2262,2261,2264,2271,2267,504,2270,2268,2272,2275,2269,2259,2263,1256],"industry":[17225],"therapeutic_areas":[17233,17245,17228,17234],"class_list":["post-3708","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-alzheimers","tag-amoxicillin","tag-beta-thalassemia","tag-cd20xcd3","tag-celgene","tag-fda","tag-h-pylori-infection","tag-los-angeles","tag-luspatercept","tag-nature-medicine","tag-red-blood-cells","tag-redhill-biopharma","tag-refractory-follicular-lymphoma","tag-regeneron","tag-regeneron-pharmaceuticals-inc","tag-regn1979","tag-rhb-105","tag-rifabutin","tag-t-cell-surface-antigen-cd3","tag-tau","tag-tgf-beta-proteins","tag-university-of-california","industry-pharmaceutical","therapeutic_areas-hematological-disorders","therapeutic_areas-neurology","therapeutic_areas-oncology","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Notizia 04\/12\/2018 - DelveInsight Business Research<\/title>\n<meta name=\"description\" content=\"The overproduction of a protein called tau has been detected in the neuron degeneration that causes Alzheimer\u2019s and other forms of dementia....\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-82\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Notizia 04\/12\/2018 - DelveInsight Business Research\" \/>\n<meta property=\"og:description\" content=\"The overproduction of a protein called tau has been detected in the neuron degeneration that causes Alzheimer\u2019s and other forms of dementia....\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-82\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-12-04T10:01:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/12\/04103829\/rs-pills-pharma-opiat.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Notizia 04\/12\/2018 - DelveInsight Business Research","description":"The overproduction of a protein called tau has been detected in the neuron degeneration that causes Alzheimer\u2019s and other forms of dementia....","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-82","og_locale":"en_US","og_type":"article","og_title":"Notizia 04\/12\/2018 - DelveInsight Business Research","og_description":"The overproduction of a protein called tau has been detected in the neuron degeneration that causes Alzheimer\u2019s and other forms of dementia....","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-82","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-12-04T10:01:16+00:00","article_modified_time":"2021-07-24T07:27:08+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/12\/04103829\/rs-pills-pharma-opiat.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-82","url":"https:\/\/www.delveinsight.com\/blog\/notizia-82","name":"Notizia 04\/12\/2018 - DelveInsight Business Research","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-82#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-82#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/12\/04103829\/rs-pills-pharma-opiat.jpg","datePublished":"2018-12-04T10:01:16+00:00","dateModified":"2021-07-24T07:27:08+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The overproduction of a protein called tau has been detected in the neuron degeneration that causes Alzheimer\u2019s and other forms of dementia....","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-82"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-82#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/12\/04103829\/rs-pills-pharma-opiat.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/12\/04103829\/rs-pills-pharma-opiat.jpg","width":1200,"height":630,"caption":"Johnson & Johnson"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/12\/04103829\/rs-pills-pharma-opiat-300x158.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">alzheimer&#039;s<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">amoxicillin<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">beta-thalassemia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">CD20xCD3<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Celgene<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">H. pylori infection<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Los Angeles<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">luspatercept<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Nature Medicine<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">red blood cells<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">RedHill Biopharma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">refractory follicular lymphoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Regeneron<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Regeneron Pharmaceuticals Inc<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">REGN1979<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">RHB-105<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">rifabutin<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">T cell surface antigen CD3<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">tau<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">TGF-beta proteins<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">University of California<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">alzheimer&#039;s<\/span>","<span class=\"advgb-post-tax-term\">amoxicillin<\/span>","<span class=\"advgb-post-tax-term\">beta-thalassemia<\/span>","<span class=\"advgb-post-tax-term\">CD20xCD3<\/span>","<span class=\"advgb-post-tax-term\">Celgene<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">H. pylori infection<\/span>","<span class=\"advgb-post-tax-term\">Los Angeles<\/span>","<span class=\"advgb-post-tax-term\">luspatercept<\/span>","<span class=\"advgb-post-tax-term\">Nature Medicine<\/span>","<span class=\"advgb-post-tax-term\">red blood cells<\/span>","<span class=\"advgb-post-tax-term\">RedHill Biopharma<\/span>","<span class=\"advgb-post-tax-term\">refractory follicular lymphoma<\/span>","<span class=\"advgb-post-tax-term\">Regeneron<\/span>","<span class=\"advgb-post-tax-term\">Regeneron Pharmaceuticals Inc<\/span>","<span class=\"advgb-post-tax-term\">REGN1979<\/span>","<span class=\"advgb-post-tax-term\">RHB-105<\/span>","<span class=\"advgb-post-tax-term\">rifabutin<\/span>","<span class=\"advgb-post-tax-term\">T cell surface antigen CD3<\/span>","<span class=\"advgb-post-tax-term\">tau<\/span>","<span class=\"advgb-post-tax-term\">TGF-beta proteins<\/span>","<span class=\"advgb-post-tax-term\">University of California<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Dec 4, 2018","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Dec 4, 2018 3:31 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3708","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=3708"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3708\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/3711"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=3708"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=3708"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=3708"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=3708"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=3708"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}